bluuebunny/crossref_metadata_2025_split huggingface dataset:
PS-C19-1: EFFECTS OF COMBINED SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS AND LOOP DIURETICS ON SYSTOLIC BLOOD PRESSURE: SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Alshehri Mohammed A , Orayj Khalid 
Published: January 2023

Background and Objective:
Sodium-glucose co-transporter-2 (SGLT2) inhibitors are considered a standard of care in patients with heart failure, chronic kidney disease (CKD), and diabetes. They have substantial positive effects on cardiovascular and renal outcomes including reducing heart failure hospitalization and slowing glomerular filtration rate (GFR) decline. Loop diuretics, on the other hand, are commonly prescribed to manage volume expansion in patients with CKD and heart failure. However, the effects of combining SGLT2 inhibitors with loop diuretics are not consistent across different clinical trials. The purpose of our meta-analysis is to investigate the effect of combined SGLT2 inhibitors and loop diuretics on systolic blood pressure.

Method:
Using Pubmed, Scopus, Web of Science, VHL, metaRegister of Controlled Trials (mRCT), and Clinical trials.gov, a systematic review and meta-analysis of literature on the effect of adding SGLT2 inhibitors to loop diuretics on blood pressure were conducted. The comprehensive review covered randomized controlled trials (RCTs), non-randomized studies, prospective, retrospective, and post hoc investigations examining the effect of SGLT2 inhibitors on systolic blood pressure in healthy and heart failure patients. The outcome was calculated using Cohen's d formula as the standardized mean difference between the first group (SGLT2 inhibitors plus loop diuretics) and the second group (loop diuretics alone). To ensure the data's validity, a sensitivity analysis was conducted using just RCTs.

Results:
Eleven studies with a total of 3343 participants met all the analysis's inclusion criteria. The pooled standardized mean difference for all studies was -0.17, indicating that SGLT2 inhibitors may have a little effect on blood pressure reduction (p value = 0.06). When RCTs were excluded from the analysis, the pooled standardized mean difference was -0.10 with a p value of 0.40.

Conclusion:
Compared to loop diuretic alone, SGLT2 inhibitors combined with loop diuretics are not associated with a significant reduction in systolic blood pressure in patients with heart failure.
PS-C19-7: HYPERTENSION INDUCED BY BEVACIZUMAB
Authors: Vanderhoeven Juan Francisco , Zanuzzi Matias Gabriel 
Published: January 2023

Objectives:
To determine the incidence of the novo hypertension in patients under bevacizumab treatment. To determine the blood pressure (BP) effect of Bevacizumab in previously diagnosed hypertensive patients. To evaluate the clinical significance of Bevacizumab induced hypertension.

Design and Methods:
Retrospective, Cohort study. Time period from 1/2015 to 06/2020 at Hospital Privado Universitario de Córdoba, Argentina. Inclusion criteria: All patients over 18 years of age. Under Bevacizumab as antineoplastic treatment, either as a single or as a combined agent. No history of previous anti-VEGF treatment. Uncontrolled BP if mean office BP > 140/90mmHg.

Results:
n = 93. Mean age 63.7 years (40 - 81). Female 52.8%. Smokers 39.8%. BMI 26.3 ± 4.8. Previous HTN 56.6%, 90% under antihypertensive treatment. Hypertensive patients were older and with greater history of familiar with HTN than those normotensives. Before Bevacizumab administration, the prevalence of uncontrolled BP was 10.9% in previous normotensive and 19.5% in previous hypertensive patients. After 12 months of treatment with Bevacizumab, 75% of those previous normotensives and 87.5% of those previous hypertensives had uncontrolled BP. There were no differences in rates of cardiovascular events (5.4%), cardiovascular deaths (2.7%) and survival between those with controlled and uncontrolled BP after the administration of Bevacizumab (Figure 1).

Conclusions:
High prevalence of uncontrolled BP after initiation of Bevacizumab. While it is widely accepted that the long-term risks of hypertension are serious, the short-term risk seems to be less relevant. BP target could be higher than in the general population, adjusted to performance status and comorbidities.
PS-C19-8: A COMPARISON OF THE MEDICATION COST AND INCIDENCE RATE OF CARDIOVASCULAR EVENTS BETWEEN INTENSIVE AND STANDARD ANTIHYPERTENSIVE PHARMACOTHERAPIES IN JAPAN
Authors: Yoshihara Hiroshi , Igarashi Ataru , Tonoike Toru , Ono Hiromitsu , Nishiuchi Susumu 
Published: January 2023

Objective:
Hypertension is a major health challenge, imposing an enormous economic burden as well as health burden worldwide. In Japan, the economic burden of hypertension and related diseases is estimated to be JPY1.7 trillion (USD 13 billion) per year, around 4% of total healthcare expenditures. This study aimed to compare treatment outcomes and costs between intensive and standard pharmacotherapies, focusing on the types of antihypertensive drugs and prescribing patterns.

Design and method:
We performed a retrospective cohort study using electronic medical record data obtained from 34 healthcare facilities in Japan. The incidence of cardiovascular events captured via claims data was set to be the outcome measure. Multivariable mixed effects Cox-proportional hazards model was applied to compare the costs and the outcomes from intensive pharmacotherapy arm (i.e., short prescribing interval/expensive drugs) and standard one (i.e., long prescribing interval/low-cost drugs).

Results:
During 6,013 person-years of follow-up, 74 events were observed. While age at the beginning of treatment had significant impact on the incidence of cardiovascular events [Hazard Ratio, 1.05 (95%CI 1.02 - 1.07); p < 0.001], no associations with cardiovascular events were found for mechanism of drug action (CCB) [1.37, (95%CI 0.839 - 2.24); p = 0.21] and for short prescribing interval (less than 30 days) [1.17 (95%CI 0.695 - 1.98); p = 0.55]. The mean medication costs per day per patient of CCB and ARB were JPY 28.9 and JPY 51.8, respectively.

Conclusions:
No significant impacts on treatment outcomes were observed for drug type and prescribing interval, although the medication costs of intensive pharmacotherapy arm were more expensive than standard arm.
PS-C19-10: SEASONAL VARIATION IN THE EFFECT OF ANTIHYPERTENSIVE TREATMENT WITH THE IRBESARTAN/HYDROCHLOROTHIAZIDE COMBINATION
Authors: Ye Xiaofei , Huang Qifang , Li Yan , Wang Jiguang 
Published: January 2023

Objective:
There is increasing awareness of seasonal variation in blood pressure. In the present analysis, we investigated seasonal variation in antihypertensive treatment effect of the irbesartan/hydrochlorothiazide combination in patients with stage 2 and 3 hypertension.

Design and Methods:
The study participants were hypertensive patients enrolled in a 12-week therapeutic study. Antihypertensive treatment was initiated with the irbesartan/hydrochlorothiazide 150/12.5 mg/day, with the possible up-titration to 300/12.5 mg/day and 300/25 mg/day at 4 and 8 weeks of follow-up. The month of treatment commencement was classified as spring/summer (May to August) and autumn/winter (September to December).

Results:
Of the 501 enrolled patients, 313 and 188 commenced antihypertensive treatment in spring/summer and autumn/winter, respectively. The mean changes in systolic/diastolic blood pressure at 8 and 12 weeks of follow-up were greater in patients who commenced treatment in autumn/winter (-32.3/-16.5 and -34.2/-16.7 mmHg, respectively) than those in spring/summer (-28.4/-13.9 and -27.1/-12.8 mmHg, respectively), with a between-season difference of 3.9 (95% confidence interval [CI], 1.4–6.4, P = 0.002)/2.6 (95% CI, 0.9–4.2, P = 0.002) mmHg and 7.0 (95% CI, 4.7–9.3, P < 0.0001)/3.9 (95% CI, 2.4–5.4, P < 0.0001) mmHg, respectively. Further subgroup analyses showed a greater between-season difference in the changes in systolic blood pressure in patients aged 55 years and older (n = 255) than those < 55 years (n = 246, 12.6 vs. 6.9 mmHg, P = 0.02), and in patients with chronic kidney disease (n = 175) than those with normal renal function (n = 326, 12.1 vs. 7.4 mmHg, P = 0.06).

Conclusions:
There is indeed seasonality in antihypertensive treatment effect, with a greater blood pressure reduction in patients who commenced treatment in cold than warm seasons.
PS-C19-12: EFFECT OF FIXED TRIPLE ANTIHYPERTENSIVE COMBINATION THERAPY ON ARTERIAL STIFFNESS IN PATIENTS WITH ARTERIAL HYPERTENSION
Authors: Yusupova Khafiza Furkat qizi , Abdullaeva Guzal Jaloliddinovna , Shukurova Dilafruz Yusupovna , Khamidullaeva Gulnoz Abdusattarovna , Sadullaeva Mohinur A , Mashkurova Zarina Tulkunovna , Masharipov Shukhrat Matkarimovich 
Published: January 2023

The purpose of the study:
to evaluate the vasoprotective efficacy of fixed triple antihypertensive therapy (AHT) in patients with arterial hypertension (AH).

Material and methods of investigation:
According to the protocol, the study included patients with I-III stages of hypertension (ESC/ESH 2018) of both sexes, without severe concomitant diseases and cardiovascular complications (acute myocardial infarction, CHF, cerebrovascular diseases, cardiac arrhythmias, diabetes), in the amount of 85 patients. The average age of patients was 57.5 ± 11.3 years, the average duration of AH was 11.6 ± 7.4 years. To all patients before treatment and 6 months after therapy office BP was measured using the Korotkov method. Vascular stiffness was determined by applanation tonometry using the SphygmoCor device (AtCor Medical, Australia); there were studied: central systolic blood pressure (cSBP), central diastolic blood pressure (cDBP), central pulse pressure (cPP), aortic augmentation (AA), aortic augmentation index (AIx), pulse wave velocity (PWV). According to obtained data, a conclusion was made about the state of arterial stiffness. The patients were prescribed fixed triple AHT in the form of a combination of perindopril/indapamide/amlodipine («Triplixam», Servier, France) in a daily dose of 5/1.25/5 mg to 10/2.5/10 mg. Results are presented as M ± SD.

Results of the study:
In general, a significant positive antihypertensive efficacy of fixed triple AHT was obtained. Analysis of indicators of central hemodynamics and arterial stiffness revealed a positive 6-month efficacy of fixed triple AHT. Thus, the cSBP index was initially 162.4 ± 29.4 mm Hg and in dynamics - 144.3 ± 17.6 mm Hg (p < 0.02); cPP index was 77.9 ± 22.3 mm Hg versus 61.3 ± 16.4 mm Hg, respectively (p < 0.02); AA index was 21.3 ± 25.1 mm Hg versus 15.6 ± 9.2 mm Hg, respectively (p < 0.05); the PWV indicator was 11.2 ± 2.8 m/sec versus 9.8 ± 2.5 m/sec, respectively (p < 0.02). At the same time, the PWV movement indicator reached the standard values.

Conclusion:
The high antihypertensive efficacy of 6-month fixed triple AHT provided a positive dynamic in the parameters of central hemodynamics and arterial stiffness in patients with AH.
PS-C20-4: SGLT2I - A POTENTIAL ANTIHYPERTENSIVE AGENT IN HYPERTENSION PATIENTS WITH TYPE 2 DIABETES MELLITUS
Authors: Doan Long Pham Phuoc , Van Huynh Minh 
Published: January 2023

Introduction:
Sodium-Glucose cotransporter 2 inhibitor is a class of treatment for type 2 diabetes mellitus (T2DM) recently recommended in the treatment of patients with heart failure. We evaluated the effect of blood pressure-lowering of this agent in patients with T2DM.

Methods:
A prospective study in all hypertensive patients with T2DM admitted to the Department of Cardiology Department of Hue Central Hospital who had not been treated with SGLT2i between 12/2020 and 05/2021. In the end, 236 patients were participating in the study, in which 110 patients received Dapagliflozin 10 mg daily with OMT and 126 patients received OTM. The patients were followed up at the hospital and 2 months after discharge. Comprehensive examination, and measurement of upper arm blood pressure (BP) with Omron HEM-7121.

Results and discussion:
The mean age was 66.77 ± 15.53. The patient had a 9 (0–40) year history of hypertension and a 5 (0–37) year history of T2DM. The baseline BP was 146.29 ± 19.17 / 83.78 ± 13.1 mmHg, with no significant difference in baseline BP values in the 2 groups of patients. The results after 2 months showed that in the group of patients in combination with SGLT2i, there was a significant decrease in the mean SBP value compared with the group of patients with OTM of 5.95 mmHg (95%CI: 2.08 - 9.82, p = 0.003) but the decrease in DBP was not significantly different (95% CI: -0.09 - 5.40, p = 0.058). Subgroup analysis showed that in the group of patients with resistant hypertension, the group of patients using SGLT2i reduced DBP more than the group of patients with OTM by 2.77 mmHg (95%CI: 1.89 - 4.24, p = 0.005) but was not significant for SBP. In contrast, in patients with isolated systolic hypertension, the SBP in the group of patients using SGLT2i decreased more than in the group without using SGLT2i by about 8.91 mmHg (95%CI: 6.20 - 11.24, p = 0.035). These results were not observed in patients with heart failure and chronic kidney disease.

Conclusion:
SGLT2i has shown potential to be used as an antihypertensive agent in patients with heart failure and chronic kidney disease and shows superior efficacy in patients with isolated systolic pressure and resistant hypertension.
PS-C20-9: ANTIPLATELET AND ANTICOAGULANT THERAPY DURING ANGIOPLASTY PROCEDURES FOR ATHEROMATOUS OR FIBROMUSCULAR DYSPLASIA RENAL ARTERY STENOSIS IN ESH EC FRENCHS CENTRES
Authors: Bouhanick Beatrice , Sfhta Members , Sublet Marilucy Lopez 
Published: January 2023

Introduction:
Recommendations framing antiplatelet therapy (APT) and/or anticoagulation (AC) therapy during renal artery angioplasty procedures remain succinct or absent. However, the usefulness of this medical therapy is supported by pathophysiology and follow-up of these arterial damage (1).

Objectives:
The aim was to describe the practice of using APT and AC in the 17 French ESH-EC during renal artery angioplasties for atheromatous stenoses (AS) or fibromuscular dysplasia stenoses (FMD).

Materials and Methods:
Sending of a questionnaire via the French Society of Hypertension mailing to collect data with a reminder 1 month later.

Results:
Are summarized in the table. 12 centres responded partially or completely for AS and 10 for FMD. 2 centres considered that they did not recruit enough; 3 did not respond.

Discussion/Conclusion:
In AS, single APT before angioplasty is the rule, while double APT is routine after angioplasty for 1 month, followed by single APT over the long term. In FMD, in most cases (90% of cases) there is no double APT before or after angioplasty (except in the case of dissection), while a single APT is continued in 60% of cases over the long term. Anticoagulants are reserved for bolus injection in operating room (with some exceptions) for both AS and FMD.
For AS, the handling of APT (duration, dose) differs, due to the lack of recommendations. In contrast, the use of AC/APT seems to be homogeneous in FMD before and during angioplasty, in accordance with the recommendations (1). New observational studies and randomized controlled trials must be part of a future international guideline.
1. Gornik HL et al. J Hypertens. 2019 Feb;37(2):229–252
Members of the French Society of Hypertension (Société Française d’Hypertension Artérielle - SFHTA): B Bouhanick, J Amar, L Amar, J Blacher, PY Courand, P Delsart, T Denolle, J Doublet, JP Fauvel, P Fesler, X Girerd, S Le Jeune, C Pelletier, P Rossignol, M Rodière, F Silhol, M Lopez-Sublet.
PS-C21-7: IMPACT OF THE TIME OF DAY PERFORMING AVS ON THE SUCCESS RATE AND SUBTYPE DIAGNOSIS IN PRIMARY ALDOSTERONISM
Authors: Yoneda Mau , Kometani Mitsuhiro , Karashima Shigehiro , Usukura Mikiya , Mori Shunsuke , Aono Daisuke , Konishi Seigo , Mai Xurong , Furukawa Kenji , Takeda Yoshiyu , Yoneda Takashi 
Published: January 2023

Purpose:
Adrenal vein sampling (AVS) is the gold-standard technique for the subtype diagnosis of primary aldosteronism (PA). Measurements of aldosterone and cortisol in adrenal venous blood are used to determine the success or failure of AVS and to diagnose the PA subtype, but these hormone secretions show diurnal change. In this study, we examined the effect of the time of AVS on the results.

Design:
Multicenter, retrospective, observational study

Setting:
Three centers in Japan

Patients:
591 patients diagnosed with PA and undergoing AVS at 3 centers were used. All patients underwent basal AVS and ACTH-stimulated AVS on the same day. 382 patients underwent AVS in the morning (AM-AVS) and 209 patients in the afternoon (PM-AVS).

Results:
In terms of Selectivity Index (SI) in AVS, there was no significant difference in the right adrenal vein in basal AVS (22 vs. 23, p = 0.26), but SI of AM-AVS group was significantly higher in the left adrenal vein (19 vs. 17, p = 0.03). 03) than PM-AVS. However, in AVS after ACTH loading, SIs of both right and left adrenal veins were significantly higher in the PM group (Right: 42 vs. 44, p = 0.03; Left: 48 vs. 50, p = 0.01). However, there was no significant difference in AVS success rates between the two groups for basal AVS (81% vs. 74%, p = 0.08) and ACTH-stimulated AVS (92% vs. 88%, p = 0.19). There was also no significant difference in the proportion of patients diagnosed with unilateral PA in basal AVS (57% vs. 48%, p = 0.09) and ACTH-stimulated AVS (17% vs. 14%, p = 0.41).

Conclusions:
In a multicenter observational study, there was no significant difference in AVS success rate or subtype diagnosis of AVS between the different AVS times.
PS-C23-8: COFFEE INTAKE AND RISK OF HYPERTENSION IN KOREAN ADULTS: RESULTS FROM KNHANES 2012–2016
Authors: Cho In Jeong , Pyun Wook Bum 
Published: January 2023

Introduction:
Coffee is the most popular and widely consumed drink in South Korea. Coffee consumption seems to have both benefits and risk with respect to hypertension. But, results from studies evaluating effect of frequency of coffee consumption on risk of hypertension are mixed and inconsistent. Hence, this study investigated the effect of frequency of coffee consumption on risk of hypertension in Korean adults.

Methods:
Data from Korean National Health and Nutrition Examination Survey (KNHANES 2012–2016) was obtained and 12133 eligible participants were selected. The consumption of coffee was obtained at baseline using a food frequency questionnaire (FFQ). Subsequently coffee intake was categorized into three categories (cups/day): < 1, 1–3, and > 3 cups/day. Hypertension status was defined as a systolic blood pressure > 140 mmHg or a diastolic blood pressure > 90 mmHg, use of antihypertensive drug treatment, or both. Multivariable logistic regression analysis was used to examine the effect of coffee consumption on risk of hypertension.

Results:
Fifty-five percent participants drank coffee 1–3 cups coffee/day. A total of 2359 participants had hypertension. In all participants more than 3 cups of coffee intake in a day was significantly reduced the risk of hypertension with Odds Ratio (OR) 0.76 (95%C.I. 0.65,0.89). Participants in middle age (40–59 years) group OR 0.76 (95% C.I. 0.63,0.93), normal range BMI OR 0.65 (95% C.I. 0.52,0.80), not diabetic OR 0.79 (95% C.I. 0.64,0.98), normal cholesterol OR 0.76 (95% C.I. 0.63,0.94) had protective effect of coffee consumption against risk of hypertension.

Conclusion:
The beneficial effect of > 3 cups of coffee intake in a day were seen in middle age, normal BMI, not diabetic and normal cholesterol participants compared to consumption of < 1 cup/day.
PS-C23-11: CREATION OF TOMATOES WITH HIGH GABA ACCUMULATION BY GENE EDITING AND THEIR HYPOTENSIVE EFFECTS
Authors: Minako Sumiyoshi , Yatabe Junichi , Ezura Hiroshi , Takayama Mariko , Nagata Hiroshi , Kawasaki Tomohiro 
Published: January 2023

Background and Purpose:
The number of functional food products containing gamma-aminobutyric acid (GABA), which is claimed to have a hypotensive effect, will exceed 300 in Japan by 2020. GABA containing foods has surpassed the number of applications for non-digestible dextrin, which is claimed to prevent high blood sugar. Sicilian Rouge High GABA tomato (High GABA tomato) is the world's first tomato that has been approved as a gene-edited food, which uses CRISPR/Cas9 to enable a dense accumulation of GABA. In this presentation, we will report the background of the development of the GABA hyper-accumulating tomato as well as the results of an in-house monitoring survey conducted on the consumption of this tomato.

Methods:
Through gene editing technology, we have successfully modified the auto-inhibitor-domain of the glutamate decarboxylase gene to enhance its activity and high GABA tomatoes were produced. Thirteen in-house monitors (5 normotensive and 8 mildly hypertensive) were asked to consume the high GABA tomatoes starting in November 2021. High GABA tomatoes were consumed fresh or cooked, with a daily dosage of 5 tomatoes. The monitored participants had their home blood pressure measured twice a day, in the morning and at night, and their blood pressure was compared between the two weeks before and the two weeks after the start of tomato consumption.

Results:
High GABA tomatoes contain 95 mg/100 g of GABA, and eating 5 tomatoes per day provided approximately 100 mg of GABA.
No clinically significant blood pressure changes were observed in the five participants with average baseline home systolic blood pressure < 135 mmHg. When the eight participants with baseline systolic blood pressure > = 135 mmHg were divided into groups, the systolic blood pressure in 3 out of 4 subjects in the upper half decreased significantly (from 155 mmHg to 150 mmHg, Δ-4.6 mmHg). On the other hand, systolic blood pressure of the lower half of the hypertensives increased significantly in 2 subjects, but the mean did not change significantly (from 137 mmHg to 139 mmHg, Δ + 1.8 mmHg).

Conclusion:
While further study is necessary, the results suggest that Sicilian Rouge High GABA tomato may contribute to blood pressure reduction when consumed by hypertensive individuals.